Search

Displaying results 2571 - 2580 of 10000 in total
  1. Drug

    Pancrelipase lipase

    go.drugbank.com/drugs/DB13147
    ApprovedInvestigational

    [A32748] The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

    Mixtures: Pancrease Mt 10, Pancrease Mt 20Products: Formula C & E
  2. Drug

    Pranoprofen

    go.drugbank.com/drugs/DB13514
    Investigational

    Pranoprofen is an anti-inflammatory agent.

    Products: OFTALAR STERIL GOZ DAMLASI 5 ML
  3. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]

  4. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.

  5. Indication

    Moderate Chronic Hand Eczema (CHE)

    go.drugbank.com/conditions/DBCOND0169739
    Drugs: Delgocitinib
    Synonyms: Moderate Chronic Hand Eczema (CHE)
  6. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    It is used in food supplements as a source of niacin (vitamin B3), where hydrolysis of 1 g (1.23 mmol) inositol hexanicotinate yields 0.91 g nicotinic acid and 0.22 g inositol. … It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate.

    Mixtures: Inositol Nicotinate 250 mg, Inositol Nicotinate 250 mg
  7. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    It promotes tumor cell survival by sequestering proapoptotic proteins and blocking the intrinsic mitochondrial apoptotic pathway. … It is the first BCL-2 inhibitor approved for MCL and the second oncology-approved BCL-2 inhibitor overall, following venetoclax.

  8. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Manufactured by Astellas and FDA approved April 10, 2008.

  9. Target

    20-ketosteroid reductase (20-hydroxysteroid dehydrogenase)

    go.drugbank.com/bio_entities/BE0009795
    EnzymeHumans and other mammals

    Inactivates 3alpha-hydroxy-5alpha-pregnan-20-one (3alpha,5alpha-THP) into less potent neurosteroid 3alpha,20alpha-dihydroxy-5alpha-pregnane (PubMed:11995921, PubMed:12604236). … Catalyzes the inactivation of 5alpha-DHT and progesterone converting them into 3alpha/beta-androstanediols and (20S)-hydroxypregn-4-en-3-one, respectively (PubMed:10998348, PubMed:24434280).

    Synonyms: CHDR, 20-alpha-HSDFunction: 17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase [NAD(P)+] activity
  10. Indication

    Severe Chronic Hand Eczema (CHE)

    go.drugbank.com/conditions/DBCOND0169740
    Drugs: Delgocitinib
    Synonyms: Severe Chronic Hand Eczema (CHE)